Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$6.87 USD
+0.22 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.85 -0.02 (-0.29%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.87 USD
+0.22 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.85 -0.02 (-0.29%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Zacks News
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
by Zacks Equity Research
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
by Zacks Equity Research
Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.
Best Momentum Stocks to Buy for April 18th
by Zacks Equity Research
VRCA, BZ and ANVS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 87, 2023.
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
by Zacks Equity Research
Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.
What's in the Cards for Bausch Health (BHC) Q2 Earnings?
by Zacks Equity Research
An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.
Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.
Verrica Pharmaceuticals Inc. (VRCA) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Verrica Pharmaceuticals Inc. (VRCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
by Zacks Equity Research
Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Down 65% in 4 Weeks, Here's Why You Should You Buy the Dip in Verrica Pharmaceuticals Inc. (VRCA)
by Zacks Equity Research
Verrica Pharmaceuticals Inc. (VRCA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Verrica Pharmaceuticals Inc. (VRCA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 70.4% in 4 Weeks
by Zacks Equity Research
Verrica Pharmaceuticals Inc. (VRCA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA
by Zacks Equity Research
Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
by Zacks Equity Research
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Does Verrica Pharmaceuticals Inc. (VRCA) Have the Potential to Rally 60% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Verrica Pharmaceuticals Inc. (VRCA) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
by Ekta Bagri
Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.